Human blood coagulation Factor XIII (FXIII) is a plasma protein that plays a crucial role in the final stages of the blood coagulation process. It is a transglutaminase enzyme that stabilizes and strengthens the fibrin clot by cross-linking fibrin chains and other proteins involved in clot formation. The active form of FXIII consists of two A subunits (FXIII-A2) and two B subunits, but it is the A subunits that have enzymatic activity.

### Detailed Description of Factor XIII-A2 Product:

1. **Composition**:
- The FXIII-A2 product is typically composed of two activated A subunits of Factor XIII. These are responsible for the enzymatic activity necessary for cross-linking fibrin.

2. **Source**:
- It can be derived from pooled human plasma or produced recombinantly. Plasma-derived products are purified from human blood donations, while recombinant products are manufactured using genetically engineered cells.

3. **Mechanism of Action**:
- Once activated by thrombin, FXIII-A2 transforms into an active enzyme that catalyzes the formation of covalent bonds between fibrin molecules. This cross-linking increases the mechanical strength and stability of the blood clot, making it more resistant to fibrinolysis (the process of clot breakdown).

4. **Indications**:
- FXIII-A2 products are used in individuals with congenital or acquired Factor XIII deficiency, a rare bleeding disorder that can lead to poor wound healing, spontaneous bleeding, and recurrent miscarriages. By supplementing FXIII levels, these products help in normal clot formation and maintenance.

5. **Administration**:
- The product is generally administered intravenously. Dosage and frequency depend on the severity of the deficiency, the clinical condition of the patient, and the specific product used.

6. **Efficacy**:
- Clinical trials and studies have demonstrated that FXIII-A2 products effectively prevent bleeding episodes in patients with FXIII deficiency. They help maintain hemostasis during surgical procedures and improve overall quality of life for affected individuals.

7. **Safety and Side Effects**:
- FXIII-A2 products are generally well-tolerated. Common side effects may include mild allergic reactions, such as rash or itching. Serious side effects are rare but can include anaphylactic reactions or thromboembolic events.

8. **Storage and Handling**:
- The product should be stored as per the manufacturer’s instructions, typically in a refrigerator at a controlled temperature. Once reconstituted, it should be used within a specified time frame to ensure efficacy and safety.

9. **Regulatory Status**:
- FXIII-A2 products are regulated by health authorities like the FDA or EMA. They undergo rigorous testing for purity, potency, and safety before approval for clinical use.

10. **Brand Names**:
- There are several brands available depending on the country, including both plasma-derived and recombinant versions. Examples include Corifact (plasma-derived) and Tretten (recombinant).

In summary, the human blood coagulation Factor XIII-A2 product is a vital therapeutic for individuals with FXIII deficiency, offering a means to achieve effective hemostasis and prevent bleeding complications.